Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer

Chih-Jung Chen¹, Ting-Hao Chen²,³, Jason Lei⁴, Ji-An Liang⁵, Po-Sheng Yang⁶, Chiun-Sheng Huang⁷, Chia-Ming Hsieh⁸, Ling-Ming Tseng⁹, Liang-Chih Liu¹,¹⁰, Skye Hung-Chen Cheng¹¹ and Kuan-Hui Shih²

¹Department of General Surgery, China Medical University Hospital, Taichung, Taiwan; ²Department of Medical Operation, Amwise Diagnostics Pte. Ltd., Singapore; ³Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan; ⁴Department of Product Development, Amwise Diagnostics Pte. Ltd., Singapore; ⁵Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan; ⁶Department of General Surgery, Mackay Memorial Hospital, Taipei, Taiwan; ⁷Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan; ⁸Department of General Surgery, Taiwan Adventist Hospital, Taipei, Taiwan; ⁹College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; ¹⁰College of Medicine, China Medical University, Taichung, Taiwan; ¹¹Department of Radiation Oncology, Koo Foundation Sun Yet-Sen Cancer Center, Taipei, Taiwan

Correspondence: Kuan-Hui Shih (kasey.shih@amwisedx.com)

Breast cancer is the most common cancer and the leading cause of cancer-related deaths in women. The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are the important biomarkers in the prognosis of breast cancer, and their expression is used to categorize breast cancer into subtypes. We aimed to analyze the concordance among ER, PR, and HER2 expression levels and breast cancer subtyping results obtained by immunohistochemistry (IHC, for protein) and reverse transcriptase-polymerase chain reaction (RT-PCR, for mRNA) and to assess the recurrence-free survival (RFS) of the different subtypes as determined by the two methods. We compared biomarker expression by IHC and RT-PCR in 397 operable breast cancer patients and categorized all patients into luminal, HER2, and triple-negative (TN) subtypes. The concordance of biomarker expression between the two methods was 81.6% (κ = 0.4075) for ER, 87.2% (κ = 0.5647) for PR, and 79.1% (κ = 0.2767) for HER2. The κ-statistic was 0.3624 for the resulting luminal, HER2, and TN subtypes. The probability of 5-year RFS was 0.78 for the luminal subtype versus 0.77 for HER2 and 0.51 for TN, when determined by IHC (P=0.0007); and 0.80, 0.71, and 0.61, respectively, when determined by the RT-PCR method (P=0.008). Based on the current evidence, subtyping by RT-PCR performs similar to conventional IHC with regard to the 5-year prognosis. The PCR method may thus provide a complementary means of subtyping when IHC results are ambiguous.

Introduction

Breast cancer is the most common cancer and the leading cause of cancer-related deaths in women, with approximately 1.7 million incident cases in 2016 [1]. The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) represent critical pathways for tumor growth and replication of breast cancer cells [2]. Molecular subtypes of breast cancer have been established based on the biological expression of these three proteins [3]. They include the luminal (ER/PR-positive and HER2-negative), HER2 (HER2-positive regardless of ER/PR status), and triple-negative (TN; ER-, PR-, and HER2-negative) breast cancer subtypes [3,4]. Surgery to remove the tumor is usually the first line of treatment for breast cancer. To reduce the risk of recurrence, patients can consider adjuvant therapies, including hormonal and HER2-targeted therapies for luminal and HER2-enriched subtypes, respectively [3]. Correct identification of the different subtypes
is thus crucial for the management of breast cancer. Conventionally, oncologists identify this important clinical information by estimating ER, PR, and HER2 protein levels using immunohistochemistry (IHC) for staining tumor cells [5,6]. Whereas it is relatively easy to perform IHC, reproducibility issues of the IHC method have been reported, probably due to the subjective nature of both the sampling process and the interpretation and scoring of the staining level [7–9]. Consequently, subtypes could be misidentified, especially in low-volume laboratories [10].

Alternatively, genomic tests have been reported recently in determining the ER (ESR1), PR (PGR), and HER2 (ERBB2) status in breast cancer [10–12]. In contrast with the protein levels determined by IHC, it is the gene expression (mRNA) levels that are determined by the genomic approach, using the reverse transcriptase-polymerase chain reaction (RT-PCR) [13,14]. The reproducibility of the genomic method is very high due to its more homogeneous sampling process, and the automated quantification by instruments without human intervention ensures objectivity [15,16].

In the present study, we compared the ER (ESR1), PR (PGR), and HER2 (ERBB2) status and the resulting subtypes of nearly 400 breast cancer specimens, as determined by the IHC and RT-PCR methods, and then evaluated their corresponding clinical performance in predicting differential breast cancer recurrence.

**Methods**

**Study population**

The breast cancer patients treated with breast-conserving surgery (BCS) or mastectomy between 2005 and 2016 at multiple medical centers in Taiwan were included in the Amwise dataset (Amwise Diagnostics Pte. Ltd.). Figure 1 shows the subject selection process. The institutional review board of each participating medical center approved the study protocol. The inclusion criteria were (1) with invasive breast cancer; (2) had received mastectomy or BCS as first treatment; (3) with ER, PR, and HER2 status confirmed by IHC and/or fluorescence in situ hybridization (FISH) at each participating center; and (4) with formalin-fixed paraffin embedded (FFPE) tissue sections for RT-PCR testing. Patients at a stage of N3 or M1 were excluded.
Determination of the ER (ESR1), PR (PGR), and HER2 (ERBB2) status

The ER, PR, and HER2 results from the IHC/FISH testing were obtained from the medical charts of each participating hospital and were considered the gold standard for positive/negative expression and subtype determination. For the determination of positive/negative expression of the ESR1, PGR, and ERBB2 genes, receiver operating characteristic (ROC) curve analysis was used. The cut-off value for positive expression of each of the three genes was determined by the optimal value of both sensitivity and specificity with respect to the IHC results. We normalized the expression of each of the three target genes (i.e., ESR1, PGR, and ERBB2) to the reference genes (ACTB, RPLP0, and TFRC) by a proprietary algorithm, which the cycle threshold \((C_t)\) is the output value from the ABI 7500Fast instrument:

\[
\Delta C_t = \frac{25 - C_t \text{(ESR1, PGR, ERBB2)} + [C_t \text{(ACTB)} + C_t \text{(RPLP0)} + C_t \text{(TFRC)}]}{3}
\]

Breast cancer subtypes were defined as follows: luminal = ER/PR-positive and HER2-negative; HER2 = HER2-positive regardless of ER/PR status; and TN = ER-, PR-, and HER2-negative.

Reverse transcription polymerase quantitative chain reaction

RNA was extracted from FFPE tissue sections (5–10 μm in thickness) with the RNeasy FFPE Kit (Qiagen, Valencia, CA, U.S.A.). The extracted RNA was stored at −80°C until use after the concentration was determined by OD with a Nanodrop spectrophotometer (Agilent RNA 6000 Nano Kit, Agilent Technologies, Santa Clara, CA, U.S.A.). A total of 2 μg RNA was used for RT-PCR using the RT² First Strand and RT² SYBR Green ROX qPCR MM Kits (Qiagen, Valencia, CA, U.S.A.). Briefly, the RT reaction was performed at 42°C for 15 min before the reaction was terminated at 95°C for 5 min. PCR was performed on the ABI 7500Fast instrument (Thermo Fisher, CA, U.S.A.) using the Standard mode with 40 cycles at 95°C for 15 s and 60°C for 45 s. Primer sequences were as follows: 5′-cacagagatgtttatagag-3′ and 5′-tacctgtgagaagaacaga-3′ for ESR1; 5′-gagtggaagacatctcaagaccag-3′ and 5′-caggcatagatgaaagga-3′ for PGR; and 5′-acactgtcatcttgatacagc-3′ and 5′-aacaagcttgtaactcagc-3′ for ERBB2. For data normalization, primers for three housekeeping genes were also included in the assay: 5′-aactcctgtagcctgtag-3′ and 5′-ccactctgctttgctg-g-3′ for ACTB; 5′-ctgtcggagacagcattac-3′ and 5′-ccacaagccagattcact-3′ for RPLP0; and 5′-gtacgtgtaacaggctcťata-3′ and 5′-cgaaagaacatctcaacagc-3′ for TFRC.

Concordance and clinical performance of subtyping by the IHC and RT-PCR methods

To evaluate the classification, the concordance between subtype determination using the IHC and RT-PCR methods was analyzed by superimposing the frequency histograms. Concordance rates were analyzed by κ-statistics. κ values of 0.4–0.6 were considered to represent moderate agreement. The clinical performance of the two methods was evaluated by performing Kaplan–Meier survival analysis to measure the probability of recurrence over a 5-year follow-up time for the three different subtypes as determined by the two methods. By using Cox proportional hazards regression for the prognosis of recurrence-free survival (RFS), univariate and multivariate analyses of the two methods were also performed with adjustment for various clinical factors, including age, tumor stage, tumor grade, N stage, and lymphovascular invasion (LVI). All analyses were performed by using R-4.0.2 software, with \(P\)-values <0.05 considered statistically significant.

Results

Characteristics of included patients

A total of 397 operable breast cancer patients were included in the present study (Table 1). Median follow-up was 51.5 months (interquartile range (IQR), 29.5–60.0). Most of the patients \((n=359, 90.4%)\) were aged 40 or older. In the subtype classification by IHC, there were 349 (87.9%) luminal patients, 28 (7.1%) HER2-positive patients, and 20 (5.0%) TN. A total of 321 (80.9%) patients exhibited absent or focal LVI, whereas 76 (19.1%) patients showed prominent LVI. Regarding tumor stage, most patients were at T1 \((n=200, 50.4%)\) or T2 \((n=176, 44.3%)\), with 21 (5.3%) at T3. The majority of patients \((n=256, 64.5%)\) were classified as N0, with 125 (31.5%) at stage N1 and 16 (4.03%) at N2. Most patients had grade I \((n=86, 21.7%)\) or grade II \((n=267, 67.3%)\) tumors, with only 44 (11.1%) at grade III.

Cut-off values for gene expression

Cut-off values for the positive expression of the ESR1, PGR, and ERBB2 genes were determined to be 22.18667, 18.2038, and 23.69193, respectively. The ROC curves for the determination of ER, PR, and HER2 expression using
### Table 1 Characteristics of included patients

| Characteristics | n=397<sup>1</sup> |
|-----------------|---------------------|
| **Age**         |                     |
| <40             | 38 (9.57%)          |
| ≥40             | 359 (90.43%)        |
| **Tumor stage** |                     |
| T1              | 200 (50.38%)        |
| T2              | 176 (44.33%)        |
| T3              | 21 (5.29%)          |
| **N stage**     |                     |
| N0              | 256 (64.48%)        |
| N1              | 125 (31.49%)        |
| N2              | 16 (4.03%)          |
| **LVI**         |                     |
| No              | 321 (80.86%)        |
| Yes             | 76 (19.14%)         |
| **Grade**       |                     |
| 1               | 86 (21.66%)         |
| 2               | 267 (67.25%)        |
| 3               | 44 (11.08%)         |
| **IHC subtype** |                     |
| Luminal         | 349 (87.91%)        |
| HER2            | 28 (7.05%)          |
| TNBC            | 20 (5.04%)          |
| **Relapse**     |                     |
| No              | 326 (82.12%)        |
| Yes             | 71 (17.88%)         |
| **Follow-up (months)** | 51.45 [29.48, 60.00] |

Abbreviation: TNBC, triple-negative breast cancer.

<sup>1</sup>Data are presented as n (%) or median [25, 75%].

---

**Figure 2.** ROC curves for the classification of gene expression by the genomic method

(A) ROC curve of ESR1 classification of gene expression, (B) ROC curve of PgR classification of gene expression, (C) ROC curve of ERBB2 classification of gene expression. IHC classification was used as the standard of accuracy.

The area under the curve values for ER (*ESR1*), PR (*PGR*), and HER2 (*ERBB2*) were 0.846, 0.873, and 0.841, respectively.
Figure 3. Gene expression of IHC-based positive and negative patients
(A) The distribution of ESR1 gene expression between ER-positive and negative patients. (B) The distribution of PgR gene expression between PR-positive and negative patients. (C) The distribution of ERBB2 gene expression between HER2-positive and negative patients. Dash line: the cut-off value for each gene expression; x-axis: the gene expression after normalization with three housekeeping genes.

Table 2 2 × 2 table for the concordance between IHC and mRNA expression

|                | ER by mRNA | Total | $\kappa$ | $P$-value$^1$ |
|----------------|------------|-------|----------|---------------|
|                | Positive   | Negative |         |               |
| ER by IHC      |            |         |          |               |
| Positive       | 288        | 67     | 355      | 0.4075        | <0.001 |
| Negative       | 6          | 36     | 42       |               |
| Total          | 294        | 103    | 397      |               |
| PR by mRNA     |            |         |          |               |
| Positive       | 301        | 41     | 342      | 0.5647        | <0.001 |
| Negative       | 10         | 45     | 55       |               |
| Total          | 311        | 86     | 397      |               |
| HER2 by mRNA   |            |         |          |               |
| Positive       | 23         | 5      | 28       | 0.2767        | <0.001 |
| Negative       | 78         | 291    | 369      |               |
| Total          | 101        | 296    | 397      |               |

$^1$from the $\kappa$ test.

Concordance and correlation between the IHC and RT-PCR methods
In the concordance comparison, concordance between the two methods was analyzed by superimposing the frequency histograms (Figure 3). The corresponding concordance rates were 81.6% ($\kappa = 0.4075$, $P<0.001$) for ER (ESR1), 87.2% ($\kappa = 0.5647$, $P<0.001$) for PR (PGR), and 79.1% ($\kappa = 0.2767$, $P<0.001$) for HER2 (ERBB2) (Table 2). The $\kappa$-statistic was 0.3624 ($P<0.001$) for the resulting luminal, HER2, and TN subtypes (Table 3). Altogether, the
Table 3 The cross-tabulation of subtype determined by mRNA and IHC

| Characteristic | mRNA-based | IHC-based | Total | \( \kappa \) | \( P\)-value \(^1\) |
|---------------|------------|-----------|-------|-------------|-------------------|
|               | Luminal    | HER2      | TNBC  |             |                   |
| IHC-based     |            |           |       |             |                   |
| Luminal       | 261        | 75        | 13    | 349         | 0.3624            |
| HER2          | 4          | 23        | 1     | 28          | <0.001            |
| TNBC          | 2          | 3         | 15    | 20          |                   |
| Total         | 267        | 101       | 29    | 397         |                   |

Abbreviation: TNBC, triple-negative breast cancer, \(^1\)from the \( \kappa \) test.

Results indicate that there was moderate agreement between the two methods for the subtyping of breast cancer.

**Probability of recurrence**

By Kaplan–Meier survival analysis, the probability of recurrence among the three subtypes was significantly different in both by the RT-PCR (\( P = 0.008 \), Figure 4A) and the IHC (\( P = 0.007 \), Figure 4B) methods. The probability of 5-year RFS in the luminal, HER2, and TN subtypes, as determined by the RT-PCR method, was 0.80 (95% confidence interval (CI): 0.74–0.87), 0.71 (0.62–0.82), and 0.61 (0.45–0.82), respectively (Figure 4A). The probability of 5-year RFS in the luminal, HER2, and TN subtypes, when determined by IHC, was 0.78 (95% CI: 0.72–0.83), 0.77 (0.62–0.95), and 0.51 (0.33–0.81), respectively (Figure 4B).

**Univariate and multivariate Cox proportional hazards’ analyses**

Univariate analysis for any recurrence by a Cox proportional hazards model revealed that subtype, either by the IHC or RT-PCR method, was a prognostic factor, especially for the TN subtype (Table 4). By the RT-PCR method, the hazard ratios of the HER2 and TN subtypes were 1.59 (95% CI: 0.94–2.68) and 2.64 (95% CI: 1.33–5.22) when compared with the luminal subtype. In contrast, by the IHC method, the hazard ratios of the HER2 and TN subtypes were 1.27 (95% CI: 0.55–2.97) and 2.89 (95% CI: 1.42–5.85) when compared with the luminal subtype.

In the multivariate analysis, subtyping either by the IHC or the RT-PCR method retained the same trends as in the univariate analysis (Table 4). By the RT-PCR method, the hazard ratios of the HER2 and TNBC subtypes were 1.75 (95% CI: 1.02–3.00) and 2.21 (95% CI: 1.05–4.62), respectively, when compared with the luminal subtype. By the IHC method, the hazard ratios of the HER2 and TNBC subtypes were 1.43 (95% CI: 0.60–3.38) and 4.29 (95% CI: 1.85–9.96), respectively, when compared with the luminal subtype.

**Discussion**

Breast cancer is the most prevalent cancer and the leading cause of cancer-related deaths in women [1]. Surgery is usually the first line of treatment, followed by systemic targeted therapy or non-targeted chemotherapy. Targeted therapies include ER-targeted hormonal therapies (tamoxifen, etc.) [17,18] and HER2-targeted monoclonal antibody therapies (herceptin, etc.) [19,20]. The prescription decision is usually based on the ER, PR, and HER2 status. The resulting subtyping information is crucial for the prognosis of the disease.

Subtyping of breast cancer is usually done by IHC staining of tumor cells for ER, PR, and HER2 detection. However, although IHC is relatively easy and inexpensive to perform, subtyping by the IHC method can be error-prone, as selection of the examined areas and assessment of the staining levels could be relatively subjective, leading to misidentification or low reproducibility across different pathologists and laboratories [7,8]. In particular, the IHC staining of HER2 can be ambiguous and requires another experimental approach to validate its results. From the practical perspective, sometimes the determination of HER2 status by using the IHC method is uncertain [21]. For example, if the IHC staining of HER2 is 2+, the FISH method, is required to double-confirm the status of HER2 receptor. Therefore, additional works are necessary to validate the results.

In the current study, we investigated the ER (ESR1), PR (PGR), and HER2 (ERBB2) status by determining their mRNA levels with a genomic (RT-PCR) approach, in contrast to protein-level determination by the IHC approach with antibody staining. The genomic method utilizes the whole tumor tissue for testing, and the expression levels are measured by an automated instrument. Despite the differences in the detection mechanisms, the results of the two methods were in moderate agreement in this cohort with regard to the determination of the ER (ESR1), PR...
Figure 4. Kaplan–Meier plot for probability of recurrence within 5 years
Kaplan–Meier plot for probability of recurrence within 5 years with subtype determined by (A) the genomic method or (B) the IHC method. (A) The RFS with subtype determined by the genomic method. (B) The RFS with subtype determined by the IHC method.
Table 4 Cox proportional hazards regression model for RFS over 5 years

| Characteristics       | Univariate  | HR (95% CI) | P-value | Model 1 | HR (95% CI) | P-value | Model 2 | HR (95% CI) | P-value |
|-----------------------|-------------|-------------|---------|---------|-------------|---------|---------|-------------|---------|
| **Age**               |             |             |         |         |             |         |         |             |         |
| <40                   |             | -           | -       | -       |             | -       |         |             |         |
| ≥40                   |             | 0.51 (0.27, 0.97) | 0.039 | 0.50 (0.25, 1.00) | 0.050 | 0.46 (0.23, 0.93) | 0.030 |
| **LVI**               |             |             |         |         |             |         |         |             |         |
| No                    |             | -           | -       | -       |             | -       |         |             |         |
| Yes                   |             | 1.32 (0.75, 2.30) | 0.338 | 0.76 (0.38, 1.53) | 0.40  | 0.67 (0.33, 1.38) | 0.30 |
| **Tumor stage**       |             |             |         |         |             |         |         |             |         |
| T1                    |             | -           | -       | -       |             | -       |         |             |         |
| T2                    |             | 1.41 (0.87, 2.29) | 0.167 | 1.08 (0.63, 1.86) | 0.80  | 1.03 (0.60, 1.77) | >0.9  |
| T3                    |             | 0.55 (0.13, 2.32) | 0.418 | 0.30 (0.07, 1.35) | 0.12  | 0.16 (0.03, 0.82) | 0.028 |
| **N stage**           |             |             |         |         |             |         |         |             |         |
| N0                    |             | -           | -       | -       |             | -       |         |             |         |
| N1                    |             | 1.23 (0.73, 2.08) | 0.443 | 1.15 (0.63, 2.09) | 0.60  | 1.02 (0.55, 1.91) | >0.9  |
| N2                    |             | 3.83 (1.85, 7.93) | <0.001 | 4.17 (1.70, 10.2) | 0.002 | 5.14 (2.10, 12.6) | <0.001 |
| **Tumor grade**       |             |             |         |         |             |         |         |             |         |
| 1                     |             | -           | -       | -       |             | -       |         |             |         |
| 2                     |             | 1.74 (0.88, 3.46) | 0.112 | 1.76 (0.84, 3.68) | 0.13  | 1.81 (0.87, 3.79) | 0.11  |
| 3                     |             | 3.10 (1.36, 7.08) | 0.007 | 3.03 (1.16, 7.90) | 0.024 | 2.93 (1.15, 7.45) | 0.024 |
| **mRNA-based subtype**|             |             |         |         |             |         |         |             |         |
| Luminal               |             | -           | -       | -       |             | -       |         |             |         |
| HER2                  |             | 1.59 (0.94, 2.68) | 0.086 | 1.75 (1.02, 3.00) | 0.043 |         |             |         |
| TNBC                  |             | 2.64 (1.33, 5.22) | 0.005 | 2.21 (1.05, 4.62) | 0.036 |         |             |         |
| **IHC-based subtype** |             |             |         |         |             |         |         |             |         |
| Luminal               |             | -           | -       | -       |             | -       |         |             |         |
| HER2                  |             | 1.27 (0.55, 2.97) | 0.573 |         |             | 1.43 (0.60, 3.38) | 0.40  |
| TNBC                  |             | 2.89 (1.42, 5.85) | 0.003 |         |             | 4.29 (1.85, 9.96) | <0.001 |

Abbreviations: HR, hazard ratio; TNBC, triple-negative breast cancer.

1 Multivariate Cox proportional hazards regression model including age, LVI, tumor stage, N stage, tumor grade, and mRNA-based subtyping.

2 Multivariate Cox proportional hazards regression model including age, LVI tumor stage, N stage, tumor grade, and IHC-based subtyping.

...and HER2 (ERBB2) levels, and the subsequent subtyping of breast cancer into luminal, HER2- enriched, or TN groups (Figure 2 and Table 2).

It is unclear what caused the discordant results for some cases in the present study, but discordance between the IHC and molecular methods has been reported by others previously [14]. This may be related to the difference in sampling, where the genomic method uses the whole tissue section whereas the IHC method examines only a few portions of the tissue sample. Other possible reasons may include low translational efficiency of mRNA into protein. Nevertheless, based on the Kaplan–Meier analysis of recurrence in the three different subtypes (Figure 3), it is intriguing that both the IHC and RT-PCR approaches performed relatively well in prognosis of RFS of the patients studied. It may thus prove prudent to supplement the IHC with the genomic method for the clinical benefit of patients in selection of appropriate therapies. For example, if the tests are positive with a patient by either the IHC or RT-PCR method, this patient should be considered for a corresponding targeted therapy to avoid undertreatment due to misidentified negative results by the IHC method, or vice versa. In fact, some IHC-negative but RT-PCR-positive patients have been reported to respond to trastuzumab therapy [20].

It should be noted that the present study has limitations. First, the IHC test results were not obtained in a central laboratory setting and thus the criteria may vary in different hospitals. Furthermore, each of the HER2 and TN subtypes represents only a relatively small proportion of the studied population. Lastly, subtypes were generated by approximation, and investigators were not in a setting completely blinded to clinical variables of the studied population.
Conclusion

Subtyping of breast cancer by complementing IHC tests with genomic tests for determining the ER (ESR1), PR (PGR), and HER2 (ERBB2) status could provide accurate classification results and further treatment of the patients can be based on the subtyping.

Data Availability

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the Amwise Diagnostics Pte. Ltd.
Ting-Hao Chen is the employee of Amwise Diagnostics Pte. Ltd; Jason Lei is Sr. Director of Product Development at Amwise Diagnostics Pte. Ltd; and Kuan-Hui Shih is the Vice-President of Medical Operations at Amwise Diagnostics Pte. Ltd.

CRediT Author Contribution

Chih-Jung Chen: Conceptualization, Resources, Project administration. Ting-Hao Chen: Data curation, Formal analysis, Writing—original draft. Jason Lei: Formal analysis, Methodology, Writing—original draft. Ji-An Liang: Resources. Po-sheng Yang: Resources. Chiu-Sheng Huang: Resources. Chia-Ming Hsieh: Resources. Ling-Ming Tseng: Resources. Liang-Chih Liu: Resources. Skye Hung-Chen Cheng: Conceptualization, Resources, Writing—review & editing. Kuan-Hui Shih: Funding acquisition, Project administration, Writing—review & editing.

Ethics Approval

The study was approved by institutional review board of each participating medical center (IRB numbers: China Medical University Hospital-Radiation Oncology (CMUH106-REC1-151), China Medical University Hospital-Surgical (CMUH107-REC3-110), Mackay Memorial Hospital (17CT040be), National Taiwan University Hospital (201610066RINA), Taiwan Adventist Hospital (107-E-05), Taipei Veterans General Hospital (2020-09-004AC), Chia-Yi Christian Hospital (IRB2019060) and Cheng Hsin General Hospital (108B-09)).

Abbreviations

BCS, breast-conserving surgery; CI, confidence interval; ER, estrogen receptor; FFPE, formalin-fixed paraffin embedded; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; LVI, lymphovascular invasion; PR, progesterone receptor; RFS, recurrence-free survival; ROC, receiver operating characteristic; RT-PCR, reverse transcriptase-polymerase chain reaction; TN, triple-negative.

References

1 Fitzmaurice, C., Akinyemiju, T.F., Global Burden of Disease Cancer Collaboration et al. (2018) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 4, 1553–1568, https://doi.org/10.1001/jamaoncol.2018.2706
2 Chung, Y.L., Sheu, M.L., Yang, S.C., Lin, C.H. and Yen, S.H. (2002) Resistance to tamoxifen- induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int. J. Cancer 97, 306–312, https://doi.org/10.1002/ijc.1614
3 Goldhirsh, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thurlimann, B. and Senn, H.J. (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22, 1736–1747, https://doi.org/10.1093/annonc/mdr304
4 Arvold, N.D., Taghian, A.G., Niemierko, A. et al. (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J. Clin. Oncol. 29, 3885–3891, https://doi.org/10.1200/JCO.2011.36.1105
5 Gandara-Cortes, M., Vazquez-Bouquete, A., Fernandez-Rodriguez, B. et al. (2018) Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis. Virchows Arch. 472, 195–203, https://doi.org/10.1007/s00428-017-2194-z
6 Hagemann, I.S. (2016) Molecular testing in breast cancer: a guide to current practices. Arch. Pathol. Lab. Med. 140, 815–824, https://doi.org/10.5858/arpc.2016-0051-RA
7 McCullough, A.E., Dell’orto, P., Reinholz, M.M. et al. (2014) Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D [Alliance]] ring study. Breast Cancer Res. Treat. 143, 485–492, https://doi.org/10.1007/s10549-013-2827-0
8 Pinder, S.E., Campbell, A.F., Bartlett, J.M. et al. (2017) Discrepancies in central review re- testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. Br. J. Cancer 116, 859–863, https://doi.org/10.1038/bjc.2017.28
9 de Gramont, A., Watson, S., Ellis, L.M. et al. (2015) Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat. Rev. Clin. Oncol. 12, 197–212, https://doi.org/10.1038/nrclinonc.2014.202
10 Viale, G., Slaets, L., Bogaerts, J. et al. (2014) High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann. Oncol. 25, 816–823, https://doi.org/10.1093/annonc/mdu026
11 Harbeck, N., Soetar, K., Wuerstlein, R. and Doisneau-Sixou, S. (2014) Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat. Rev. 40, 434–444, https://doi.org/10.1016/j.ctrv.2013.09.014
12 Caan, B.J., Sweeney, C., Habel, L.A. et al. (2014) Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer. Epidemiol. Biomarkers Prev. 23, 725–734, https://doi.org/10.1158/1055-9965.EPI-13-1017
13 Laible, M., Hartmann, K., Gurtler, C. et al. (2019) Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy. BMC Cancer 19, 694, https://doi.org/10.1186/s12885-019-5890-z
14 Wu, N.C., Wong, W., Ho, K.E. et al. (2018) Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform. Breast Cancer Res. Treat. 172, 327–338, https://doi.org/10.1007/s10549-018-4889-5
15 Noske, A., Loibl, S., Darb-Esfahani, S. et al. (2011) Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res. Treat. 126, 109–117, https://doi.org/10.1007/s10549-010-1316-y
16 Sinn, H.P., Schneeweiss, A., Keller, M. et al. (2017) Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer 17, 124, https://doi.org/10.1186/s12885-017-3111-1
17 Kim, C., Tang, G., Pogue-Geile, K.L. et al. (2011) Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J. Clin. Oncol. 29, 4160–4167, https://doi.org/10.1200/JCO.2010.32.9615
18 Alfarsi, I., Johnston, S., Liu, D.X., Rakha, E. and Green, A.R. (2018) Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. Histopathology 73, 545–558, https://doi.org/10.1111/his.13523
19 Loi, S., Dafni, U., Karlis, D. et al. (2016) Effects of estrogen receptor and human epidermal growth factor receptor-2 levels on the efficacy of trastuzumab: a secondary analysis of the HERA Trial. JAMA Oncol. 2, 1040–1047, https://doi.org/10.1001/jamaoncol.2016.0339
20 Pogue-Geile, K.L., Kim, C., Jeong, J.H. et al. (2013) Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J. Natl. Cancer Inst. 105, 1782–1788, https://doi.org/10.1093/jnci/djt321
21 Mrozowski, A., Olszewski, W.P., Piaścik, A. and Olszewski, W.T. (2004) HER2 status in breast cancer determined by IHC and FISH: comparison of the results. Polish J. Pathol. 55, 165–171